Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Controlling alpha for mixed effects models for repeated measures.

Ye Z, Bekele BN.

J Biopharm Stat. 2018;28(6):1055-1077. doi: 10.1080/10543406.2018.1439052. Epub 2018 Feb 20.

PMID:
29461924
2.

Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.

Dai B, Yan S, Lara-Guerra H, Kawashima H, Sakai R, Jayachandran G, Majidi M, Mehran R, Wang J, Bekele BN, Baladandayuthapani V, Yoo SY, Wang Y, Ying J, Meng F, Ji L, Roth JA.

PLoS One. 2015 Jun 8;10(6):e0123967. doi: 10.1371/journal.pone.0123967. eCollection 2015.

3.

The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.

Meng J, Majidi M, Fang B, Ji L, Bekele BN, Minna JD, Roth JA.

PLoS One. 2013 Oct 17;8(10):e77067. doi: 10.1371/journal.pone.0077067. eCollection 2013.

4.

Analysis of Partially Incomplete Tables of Breast Cancer Characteristics with an Ordinal Variable.

Bekele BN, Nieto-Barajas LE, Munsell MF.

J Stat Theory Pract. 2012 Dec;6(4):725-744.

5.

Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.

Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS.

Clin Cancer Res. 2012 Mar 15;18(6):1641-54. doi: 10.1158/1078-0432.CCR-11-2324. Epub 2012 Jan 24.

6.

Borrowing strength with nonexchangeable priors over subpopulations.

Leon-Novelo LG, Bekele BN, Müller P, Quintana F, Wathen K.

Biometrics. 2012 Jun;68(2):550-8. doi: 10.1111/j.1541-0420.2011.01693.x. Epub 2011 Oct 31.

7.

Neurocognitive function before and after surgery for insular gliomas.

Wu AS, Witgert ME, Lang FF, Xiao L, Bekele BN, Meyers CA, Ferson D, Wefel JS.

J Neurosurg. 2011 Dec;115(6):1115-25. doi: 10.3171/2011.8.JNS11488. Epub 2011 Sep 9.

PMID:
21905800
8.

Activating enhancer-binding protein-2β nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection.

Kim MP, Chen Y, Bekele BN, Lopez A, Khanna A, Chen JQ, Spitz MR, Behrens C, Solis L, Wismach M, Ji L, Wistuba II, Roth JA, Katz RL.

Ann Thorac Surg. 2011 Sep;92(3):1044-50. doi: 10.1016/j.athoracsur.2011.04.029.

9.

Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model.

Doucette T, Rao G, Yang Y, Gumin J, Shinojima N, Bekele BN, Qiao W, Zhang W, Lang FF.

Neoplasia. 2011 Aug;13(8):716-25.

10.

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Cancer. 2012 Feb 1;118(3):848-55. doi: 10.1002/cncr.26341. Epub 2011 Jul 12.

11.

Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.

de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV.

Clin Cancer Res. 2011 Jul 15;17(14):4872-81. doi: 10.1158/1078-0432.CCR-11-0271. Epub 2011 Jun 1.

12.

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.

Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA.

Cancer. 2011 May 15;117(10):2112-9. doi: 10.1002/cncr.25769. Epub 2010 Nov 29. Erratum in: Cancer. 2012 May 1;118(9):2560. Johnson, Faye M [added].

13.

Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib.

Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L.

Cancer Chemother Pharmacol. 2011 Oct;68(4):889-96. doi: 10.1007/s00280-011-1567-2. Epub 2011 Feb 3.

PMID:
21290244
14.

Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.

Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H.

Cancer. 2010 Dec 15;116(24):5659-66. doi: 10.1002/cncr.25365.

15.

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.

Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA.

PLoS One. 2010 Nov 29;5(11):e14124. doi: 10.1371/journal.pone.0014124.

16.

A modified toxicity probability interval method for dose-finding trials.

Ji Y, Liu P, Li Y, Bekele BN.

Clin Trials. 2010 Dec;7(6):653-63. doi: 10.1177/1740774510382799. Epub 2010 Oct 8.

17.

Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms.

Stewart DJ, Johnson C, Lopez A, Glisson B, Rhee JM, Bekele BN.

J Thorac Oncol. 2010 Nov;5(11):1826-34. doi: 10.1097/JTO.0b013e3181f387c7.

18.

Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ.

J Clin Oncol. 2010 Oct 20;28(30):4609-15. doi: 10.1200/JCO.2010.30.5474. Epub 2010 Sep 20.

19.

Adaptive dose insertion in early phase clinical trials.

Hu B, Bekele BN, Ji Y.

Clin Trials. 2013 Apr;10(2):216-24. doi: 10.1177/1740774510382800. Epub 2010 Sep 6.

PMID:
20819841
20.

Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.

Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Bekele BN, Qiao W, Levin VA.

J Neurooncol. 2011 Apr;102(2):273-80. doi: 10.1007/s11060-010-0313-7. Epub 2010 Jul 23.

21.

Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.

Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, Wistuba II.

Clin Cancer Res. 2010 Jul 15;16(14):3743-53. doi: 10.1158/1078-0432.CCR-09-3352. Epub 2010 Jun 9.

22.

Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience.

Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR.

Neuro Oncol. 2010 Aug;12(8):862-70. doi: 10.1093/neuonc/noq009. Epub 2010 Feb 5.

23.

Comparison between established and the Worldwide Esophageal Cancer Collaboration staging systems.

Gaur P, Hofstetter WL, Bekele BN, Correa AM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Rice TW, Swisher SG.

Ann Thorac Surg. 2010 Jun;89(6):1797-1803, 1804.e1-3; discussion 1803-4. doi: 10.1016/j.athoracsur.2010.02.048.

PMID:
20494031
24.

Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.

Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G.

Epigenetics. 2010 Aug 16;5(6):499-508. Epub 2010 Aug 16.

25.

Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF.

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1487-95. doi: 10.1016/j.ijrobp.2009.12.061. Erratum in: Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):6. Grewal, Jai [added].

27.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM.

J Clin Oncol. 2010 Apr 10;28(11):1856-62. doi: 10.1200/JCO.2009.25.4888. Epub 2010 Mar 8.

28.

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.

Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD.

Neuro Oncol. 2010 Feb;12(2):116-21. doi: 10.1093/neuonc/nop020. Epub 2009 Dec 14. Erratum in: Neuro Oncol. 2010 Jun;12(6):617.

29.

EphA2 in the early pathogenesis and progression of non-small cell lung cancer.

Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, Dong W, Bekele BN, Wistuba I, Johnson FM.

Cancer Prev Res (Phila). 2009 Dec;2(12):1039-49. doi: 10.1158/1940-6207.CAPR-09-0212. Epub 2009 Nov 24.

30.

Assessing toxicities in a clinical trial: Bayesian inference for ordinal data nested within categories.

Leon-Novelo LG, Zhou X, Bekele BN, Müller P.

Biometrics. 2010 Sep;66(3):966-74. doi: 10.1111/j.1541-0420.2009.01359.x.

31.

Molecular prognosticators of complex karyotype soft tissue sarcoma outcome: a tissue microarray-based study.

Lahat G, Tuvin D, Wei C, Wang WL, Pollock RE, Anaya DA, Bekele BN, Corely L, Lazar AJ, Pisters PW, Lev D.

Ann Oncol. 2010 May;21(5):1112-20. doi: 10.1093/annonc/mdp459. Epub 2009 Oct 29.

PMID:
19875755
32.

Pomalidomide is active in the treatment of anemia associated with myelofibrosis.

Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM.

J Clin Oncol. 2009 Sep 20;27(27):4563-9. doi: 10.1200/JCO.2008.21.7356. Epub 2009 Aug 3.

33.

Risk-group-specific dose finding based on an average toxicity score.

Bekele BN, Li Y, Ji Y.

Biometrics. 2010 Jun;66(2):541-8. doi: 10.1111/j.1541-0420.2009.01297.x. Epub 2009 Jul 23.

34.

Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population.

Kassis ES, Vaporciyan AA, Swisher SG, Correa AM, Bekele BN, Erasmus JJ, Hofstetter WL, Komaki R, Mehran RJ, Moran CA, Pisters KM, Rice DC, Walsh GL, Roth JA.

J Thorac Cardiovasc Surg. 2009 Aug;138(2):412-418.e1-2. doi: 10.1016/j.jtcvs.2009.01.033. Epub 2009 May 28.

35.

Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer.

Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM.

Clin Cancer Res. 2009 Jul 1;15(13):4423-30. doi: 10.1158/1078-0432.CCR-09-0473. Epub 2009 Jun 16.

36.

Mammography capacity impact on screening rates and breast cancer stage at diagnosis.

Elting LS, Cooksley CD, Bekele BN, Giordano SH, Shih YC, Lovell KK, Avritscher EB, Theriault R.

Am J Prev Med. 2009 Aug;37(2):102-8. doi: 10.1016/j.amepre.2009.03.017. Epub 2009 Jun 12.

PMID:
19524392
37.

Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases.

Oh Y, Taylor S, Bekele BN, Debnam JM, Allen PK, Suki D, Sawaya R, Komaki R, Stewart DJ, Karp DD.

Cancer. 2009 Jul 1;115(13):2930-8. doi: 10.1002/cncr.24333.

38.

Bayesian modeling of follow-up studies with missing data.

Stamey JD, Bekele BN, Powers S.

Ann Epidemiol. 2009 Jun;19(6):416-22. doi: 10.1016/j.annepidem.2009.01.012. Epub 2009 Apr 18.

PMID:
19375944
39.

Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.

Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C, Wistuba II.

Mod Pathol. 2009 May;22(5):668-78. doi: 10.1038/modpathol.2009.19. Epub 2009 Mar 6.

40.
41.

Adaptive randomization for multiarm comparative clinical trials based on joint efficacy/toxicity outcomes.

Ji Y, Bekele BN.

Biometrics. 2009 Sep;65(3):876-84. doi: 10.1111/j.1541-0420.2008.01175.x. Epub 2009 Jan 23.

PMID:
19173694
42.

Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung.

McDonald JM, Pelloski CE, Ledoux A, Sun M, Raso G, Komaki R, Wistuba II, Bekele BN, Aldape K.

Clin Cancer Res. 2008 Dec 1;14(23):7832-7. doi: 10.1158/1078-0432.CCR-08-0565.

43.

VEGF Trap induces antiglioma effect at different stages of disease.

Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK.

Neuro Oncol. 2008 Dec;10(6):940-5. doi: 10.1215/15228517-2008-061. Epub 2008 Aug 14.

44.

Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer.

Seo HS, Liu DD, Bekele BN, Kim MK, Pisters K, Lippman SM, Wistuba II, Koo JS.

Cancer Res. 2008 Aug 1;68(15):6065-73. doi: 10.1158/0008-5472.CAN-07-5376.

45.

Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.

Li Y, Bekele BN, Ji Y, Cook JD.

Stat Med. 2008 Oct 30;27(24):4895-913. doi: 10.1002/sim.3329.

46.

New perspectives for staging and prognosis in soft tissue sarcoma.

Lahat G, Tuvin D, Wei C, Anaya DA, Bekele BN, Lazar AJ, Pisters PW, Lev D, Pollock RE.

Ann Surg Oncol. 2008 Oct;15(10):2739-48. doi: 10.1245/s10434-008-9970-6. Epub 2008 Jun 3.

PMID:
18521685
47.

Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis.

Nakamizo A, Amano T, Zhang W, Zhang XQ, Ramdas L, Liu TJ, Bekele BN, Shono T, Sasaki T, Benedict WF, Sawaya R, Lang FF.

Neuro Oncol. 2008 Jun;10(3):275-91. doi: 10.1215/15228517-2008-015. Epub 2008 Apr 28.

48.

Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.

Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EB, Shih YC, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston K.

J Clin Oncol. 2008 Feb 1;26(4):606-11. doi: 10.1200/JCO.2007.13.8222.

PMID:
18235119
49.

Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia.

Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M.

Int J Lab Hematol. 2009 Feb;31(1):97-105. doi: 10.1111/j.1751-553X.2007.01010.x. Epub 2008 Jan 7.

50.

Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer.

Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN, Minna JD, Moran C, Roth JA, Ji L, Wistuba II.

Clin Cancer Res. 2008 Jan 1;14(1):41-7. doi: 10.1158/1078-0432.CCR-07-1252.

Supplemental Content

Loading ...
Support Center